Gomes-Pereira Mário, Monckton Darren G
Inserm U383, Clinique Maurice Lamy, Hôpital Necker Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.
Mutat Res. 2006 Jun 25;598(1-2):15-34. doi: 10.1016/j.mrfmmm.2006.01.011. Epub 2006 Feb 28.
A mounting number of inherited human disorders, including Huntington disease, myotonic dystrophy, fragile X syndrome, Friedreich ataxia and several spinocerebellar ataxias, have been associated with the expansion of unstable simple sequence DNA repeats. Despite a similar genetic basis, pathogenesis in these disorders is mediated by a variety of both loss and gain of function pathways. Thus, therapies targeted at downstream pathology are likely to be disease specific. Characteristically, disease-associated expanded alleles in these disorders are highly unstable in the germline and somatic cells, with a tendency towards further expansion. Whereas germline expansion accounts for the phenomenon of anticipation, tissue-specific, age-dependent somatic expansion may contribute towards the tissue-specificity and progressive nature of the symptoms. Thus, somatic expansion presents as a novel therapeutic target in these disorders. Suppression of somatic expansion should be therapeutically beneficial, whilst reductions in repeat length could be curative. It is well established that both cis- and trans-acting genetic modifiers play key roles in the control of repeat dynamics. Importantly, recent data have revealed that expanded CAG.CTG repeats are also sensitive to a variety of trans-acting chemical modifiers. These data provide an exciting proof of principle that drug induced suppression of somatic expansion might indeed be feasible. Moreover, as our understanding of the mechanism of expansion is refined more rational approaches to chemical intervention in the expansion pathway can be envisioned. For instance, the demonstration that expansion of CAG.CTG repeats is dependent on the Msh2, Msh3 and Pms2 genes, highlights components of the DNA mismatch repair pathway as therapeutic targets. In addition to potential therapeutic applications, the response of expanded simple repeats to genotoxic assault suggests such sequences could also have utility as bio-monitors of environmentally induced genetic damage in the soma.
越来越多的人类遗传性疾病,包括亨廷顿舞蹈症、强直性肌营养不良症、脆性X综合征、弗里德赖希共济失调症以及多种脊髓小脑共济失调症,都与不稳定的简单序列DNA重复序列的扩增有关。尽管有着相似的遗传基础,但这些疾病的发病机制是由多种功能丧失和功能获得途径介导的。因此,针对下游病理的疗法可能具有疾病特异性。这些疾病的典型特征是,与疾病相关的扩增等位基因在生殖细胞系和体细胞中高度不稳定,且有进一步扩增的趋势。生殖细胞系扩增导致了遗传早现现象,而组织特异性、年龄依赖性的体细胞扩增可能导致症状的组织特异性和进行性。因此,体细胞扩增是这些疾病中一个新的治疗靶点。抑制体细胞扩增在治疗上应是有益的,而重复序列长度的缩短可能具有治愈作用。众所周知,顺式和反式作用的遗传修饰因子在控制重复序列动态中起关键作用。重要的是,最近的数据表明,扩增的CAG.CTG重复序列对多种反式作用的化学修饰因子也敏感。这些数据提供了一个令人兴奋的原理证明,即药物诱导的体细胞扩增抑制可能确实可行。此外,随着我们对扩增机制的理解更加精确,可以设想对扩增途径进行化学干预的更合理方法。例如,CAG.CTG重复序列的扩增依赖于Msh2、Msh3和Pms2基因的证明,突出了DNA错配修复途径的组成部分作为治疗靶点。除了潜在的治疗应用外,扩增的简单重复序列对基因毒性攻击的反应表明,这些序列也可用作体细胞中环境诱导遗传损伤的生物监测指标。